Malignant Mesothelioma, Hypoalbuminaemia and the Effect ofCarboplatin/Pemetrexed on Survival

Clinical Oncology

Volumn 25, Issue 12, 2013, Pages 713-718

  Murphy, S ^a   Probert, G ^a   Anderson, J ^a   Pollock, S ^a   Taylor, I ^a   Clague, H ^a   Sridharan, K ^a  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; ECOG performance status; Hypoalbuminaemia; Mesothelioma; Pemetrexed; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CARBOPLATIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PEMETREXED;

AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; ELECTROCORTICOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOALBUMINEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE;

CARBOPLATIN; ECOG PERFORMANCE STATUS; HYPOALBUMINAEMIA; MESOTHELIOMA; PEMETREXED; PROGNOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; HYPOALBUMINEMIA; LUNG NEOPLASMS; MALE; MESOTHELIOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84887023390     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.08.009     Document Type: Article

References (25)

1. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. NEngl J Med 2005, 353:1591-1603.
2. Riaz S.P., Coupland V., Luchtenborg M., et al. Mesothelioma incidence projections in South East England. Eur Respir J 2012, 40:965-968.
3. Health and Safety Executive (HSE) Mesothelioma mortality in Great Britain 1968-2010 2012, Available at. http://www.hse.gov.uk/statistics/causdis/mesothelioma/index.htm.
4. BTS Statement on Malignant Mesothelioma in the United Kingdom British Thoracic Society Standards of Care Committee. Thorax 2007, 62:ii1-ii19.
5. Peake M., Lemon J., Darlison L., et al. Chemotherapy in Mesothelioma Project ChiMP, Mesothelioma, UK March 2011, Available at. http://www.mesothelioma.uk.com/news-32.htm.
6. Green J.A., Dundar Y., Dodd S.R., et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma (Review). The Cochrane Library 2009, (Issue 1). Art. No.: CD005574. 10.1002/14651858.CD005574.pub2.
7. National Institute for Health and Clinical Excellence Pemetrexed for treatment of malignant from pleural mesothelioma. NICE technology appraisal guidance 135 2008, Available at. http://www.nice.org.uk/nicemedia/pdf/TA135guidance.pdf.
8. Scherpereel A., Astoul P., Baas P., et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010, 35:479-495.
9. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655.
10. Charlson M.E., Pompei P., Ales K.L., et al. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40(5):373-383.
11. Peto J., Decarli A., La Vecchia C., et al. The European mesothelioma epidemic. Br J Cancer 1999, 79(3/4):666-672.
12. Chapman A., Mulrennan S., Ladd B., et al. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008, 63:435-439.
13. Yates D.H., Corrin B., Stidolph P.N., et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997, 52:507-512.
14. Damhuis R.A.M., Schroten C., Burgers J. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012, 40:185-189.
15. Montanaro F., Rosato R., Gangemi M., et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer 2009, 124:201-207.
16. Musk A.W., Olsen N., Alfonso H., et al. Predicting survival in malignant mesothelioma. Eur Respir J 2011, 38:1420-1424.
17. Pilling J.E., Dusmet M.E., Ladas G., et al. Prognostic factors for survival after surgical palliation of malignant pleural effusion. JThorac Oncol 2010, 5(10):544-550.
18. Bernard A., de Dompsure R.B., Hagry O., et al. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg 2002, 4:213-217.
19. Forrest L., McMillan D., McArdle C., et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer 2003, 89:1028-1030.
20. Curran D., Sahmoud T., Therasse P. Prognostic factors in patients with plural mesothelioma, the European Organisation for Research and Treatment of Cancer Experience. JClin Oncol 1998, 16:45-52.
21. Kovac V., Zwitter M., Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012, 46(2):136-144.
22. Muers M.F., Stephens R.J., Fisher P., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
23. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. JClin Oncol 2003, 21:2636-2644.
24. Hughes A., Calvert P., Azzabi A., et al. Phase 1 clinical and pharmacokinetic study of premetrexed and carboplatin in patients with malignant plural mesothelioma. JClin Oncol 2002, 20(16):3533-3544.
25. Ceresoli G.L., Zucali P.A., Favaretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. JClin Oncol 2006, 24:1443-1448.